Global Lentiviral Vector CDMO Market Size & Trends Report Segmented by Phase (Preclinical, Clinical, Commercial), Application (Gene Therapy, Cell Therapy, Vaccines), End User (Pharmaceutical Companies, Biotech Companies) & Regional Forecasts to 2030

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; technological advancements in lentiviral vector production; growing investments in biopharmaceutical R&D and increasing strategic partnerships and collaborations are some of the key factors driving the lentiviral vector CDMO market. 

Report Overview

Lentiviral vector contract development and manufacturing organization (CDMO) specializes in producing lentiviral vectors, critical for delivering genetic material in advanced therapies like CAR-T and gene therapies. These organizations offer comprehensive services, including vector design, process development, analytical testing, and large-scale GMP manufacturing. Leveraging state-of-the-art facilities and technical expertise, CDMOs ensure high-quality, regulatory-compliant production, helping biotech and pharmaceutical companies overcome manufacturing challenges. By partnering with CDMOs, companies can accelerate clinical trials, reduce time-to-market, and focus on research and innovation. Lentiviral Vector CDMOs play a vital role in advancing personalized medicine and addressing the growing demand for gene and cell therapies.

To learn more about the research report, download a sample report.

Growing demand for gene and cell therapies to propel market demand

The growing demand for gene and cell therapies is a key driver of the lentiviral vector CDMO market growth. These therapies, such as CAR-T and gene editing, rely on lentiviral vectors to deliver genetic material into target cells. With an increasing approvals and clinical trials for gene and cell therapies, the need for scalable, high-quality vector manufacturing has surged. CDMOs offer advanced technologies, regulatory expertise, and large-scale production capabilities, enabling biotech and pharma companies to meet rising demands. This trend accelerates the development and commercialization of innovative therapies, solidifying the role of lentiviral vector CDMOs in the expanding biopharma industry.

To learn more about the research report, download a sample report.

Technological advancements in lentiviral vector production are driving the market growth

Technological advancements in lentiviral vector production are driving the lentiviral vector CDMO market by improving manufacturing efficiency, scalability, and cost-effectiveness. Innovations such as suspension-based production systems, optimized upstream and downstream processes, and automation enable higher yields and consistent quality. Advances in vector engineering, including self-inactivating and pseudotyped vectors, enhance safety and transduction efficiency, making them more suitable for clinical applications. These improvements attract biopharma companies seeking reliable, cutting-edge solutions for gene and cell therapies. By adopting these technologies, CDMOs can meet growing demand, reduce production timelines, and strengthen their position in the competitive biopharma landscape.

Competitive Landscape Analysis

The global lentiviral vector CDMO market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific Inc., Catalent, Inc, ProBio, Revvity, Charles River Laboratories, Lonza, Oxford Biomedica PLC, Wuxi Advanced Therapies, ProBioGen AG, and AGC Biologics; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Report Scope	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
Growth Rate	8%
Market Drivers	Growing demand for gene and cell therapies Expanding pipeline of gene therapy products Technological advancements in lentiviral vector production Growing investments in biopharmaceutical R&D Increasing strategic partnerships and collaborations
Attractive Opportunities	Development of next-generation vectors Increased focus on personalized medicine Emerging markets
Segment Scope	Phase, Application, End User
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	Thermo Fisher Scientific Inc., Catalent, Inc, ProBio, Revvity, Charles River Laboratories, Lonza, Oxford Biomedica Plc, Wuxi Advanced Therapies, ProBioGen AG, and AGC Biologics among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Market Segmentation

This report by Medi-Tech Insights provides thesize of the global lentiviral vector CDMO market at theregional- and country-level from 2023 to 2030. The report further segments the market based on phase, application, end user.

• Market Size & Forecast (2025-2030), By Phase, USD Million
  • Preclinical
  • Clinical
  • Commercial
• Market Size & Forecast (2025-2030), By Application, USD Million
  • Gene Therapy
  • Cell Therapy
  • Vaccines
  • Others
• Market Size & Forecast (2025-2030), By End User, USD Million
  • Pharmaceutical Companies
  • Biotech Companies
  • Other End Users
• Market Size & Forecast (2025-2030), By Region, USD Million
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa